Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13 per cent in Q1.
Implementation of an abbreviated approval pathway for follow-on biologics could result in savings of almost $10bn over a decade, according to a report from the Congressional Budget Office (CBO).
The US Biotechnology Industry Organisation (BIO) has fuelled even
further the ongoing debate over the potential approval path for
follow-on biologics in the country with the release of a white
paper this week that stressed that 'generic'...
